Send to

Choose Destination
Muscle Nerve. 2018 Jun;57(6):875-883. doi: 10.1002/mus.26028. Epub 2017 Dec 20.

Chronic inflammatory demyelinating polyneuropathy and malignancy: A systematic review.

Author information

School of Life and Health Sciences, Aston Brain Centre, Aston University, Aston Triangle, Birmingham, B4 7ET, United Kingdom.
Regional Neuromuscular Service, University Hospitals Birmingham, Birmingham, United Kingdom.
Reference Centre for Neuromuscular Diseases and ALS, Centre Hospitalier Universitaire La Timone, Marseille, France.
Aix-Marseille University, Inserm, GMGF, Marseille, France.


A systematic review of the literature was performed on the association of chronic inflammatory demyelinating polyneuropathy (CIDP) with malignancy. Hematological disorders are the most common association, particulalry non-Hodgkin lymphoma. CIDP frequently precedes the malignancy diagnosis, and there is a favorable CIDP response to treatment more than 70% of the time. Melanoma is the second most common association and may be accompanied by antiganglioside antibodies; CIDP shows a good response to immunotherapy. Other cancers are rare, with variable timings and presentations but good responses to immunomodulation and/or cancer therapy. Unusual neurological features such as ataxia, distal/upper limb predominance, or cranial/respiratory/autonomic involvement may suggest associated malignancy as may abdominal pain, diarrhea/constipation, poor appetite/weight loss, dermatological lesions, and lymphadenopathy. In the appropriate clinical and electrophysiological setting, CIDP associated with cancer should be considered. Immunomodulatory therapy, cancer treatment alone, or a combination may be effective. Muscle Nerve 57: 875-883, 2018.


cancer; carcinoma; chronic inflammatory demyelinating polyneuropathy; lymphoma; malignancy; melanoma


Supplemental Content

Full text links

Icon for Wiley
Loading ...
Support Center